{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:12:35Z","timestamp":1784056355521,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,11]]},"DOI":"10.7759\/cureus.27881","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T11:44:15Z","timestamp":1660218255000},"source":"Crossref","is-referenced-by-count":1,"title":["Treatment Modalities for Dementia in Down\u2019s Syndrome: A Literature Review"],"prefix":"10.7759","author":[{"given":"Smriti","family":"Lamsal Lamichhane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaiishnavi","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collins O","family":"Opara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhana Yaqoob","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gargi","family":"Kabiraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humaira","family":"Kauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimee J","family":"Palakeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazin","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phani","family":"Chaduvula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanika","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10091882","article-title":"The association between physical activity and CAMDEX-DS changes prior to the onset of Alzheimer\u2019s disease in Down Syndrome","volume":"10","author":"Pape SE","year":"2021","unstructured":"Pape SE, Baksh RA, Startin C, Hamburg S, Hithersay R, Strydom A. The association between physical activity and CAMDEX-DS changes prior to the onset of Alzheimer\u2019s disease in Down Syndrome. J Clin Med. 2021, 10:10.3390\/jcm10091882","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011546.pub2","article-title":"Pharmacological interventions for cognitive decline in people with Down syndrome","author":"Livingstone N","year":"2015","unstructured":"Livingstone N, Hanratty J, McShane R, Macdonald G. Pharmacological interventions for cognitive decline in people with Down syndrome. Cochrane Database Syst Rev. 2015, CD011546. 10.1002\/14651858.CD011546.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00136","article-title":"Role of metal ions in the cognitive decline of Down syndrome","volume":"6","author":"Malakooti N","year":"2014","unstructured":"Malakooti N, Pritchard MA, Adlard PA, Finkelstein DI. Role of metal ions in the cognitive decline of Down syndrome. Front Aging Neurosci. 2014, 6:136. 10.3389\/fnagi.2014.00136","journal-title":"Front Aging Neurosci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-54299-1.00001-7","article-title":"Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future","volume":"197","author":"de la Torre R","year":"2012","unstructured":"de la Torre R, Dierssen M. Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future. Prog Brain Res. 2012, 197:1-14. 10.1016\/B978-0-444-54299-1.00001-7","journal-title":"Prog Brain Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/724904","article-title":"Oxidative stress and Down syndrome: a route toward Alzheimer-like dementia","volume":"2012","author":"Perluigi M","year":"2012","unstructured":"Perluigi M, Butterfield DA.  Oxidative stress and Down syndrome: a route toward Alzheimer-like dementia\r\n. Curr Gerontol Geriatr Res. 2012, 2012:724904. 10.1155\/2012\/724904","journal-title":"Curr Gerontol Geriatr Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61676-0","article-title":"Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomized, double-blind, placebo-controlled trial. The","volume":"379","author":"Hanney M","year":"2012","unstructured":"Hanney M, Prasher V, Williams N, et al.. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomized, double-blind, placebo-controlled trial. The. Lancet. 2012, 379:528-36. 10.1016\/S0140-6736(11)61676-0","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22125","article-title":"Tiny toes to tau tangles: Down's syndrome and its association with Alzheimer's disease","volume":"14","author":"Puttagunta SM","year":"2022","unstructured":"Puttagunta SM, Islam R, Kundu S, et al.. Tiny toes to tau tangles: Down's syndrome and its association with Alzheimer's disease. Cureus. 2022, 14:e22125. 10.7759\/cureus.22125","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109573","article-title":"Reducing the progression of Alzheimer's disease in Down syndrome patients with micro-dose lithium","volume":"137","author":"Priebe GA","year":"2020","unstructured":"Priebe GA, Kanzawa MM. Reducing the progression of Alzheimer's disease in Down syndrome patients with micro-dose lithium. Med Hypotheses. 2020, 137:109573. 10.1016\/j.mehy.2020.109573","journal-title":"Med Hypotheses"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8308-8","article-title":"Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments","volume":"264","author":"Castro P","year":"2017","unstructured":"Castro P, Zaman S, Holland A. Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments. J Neurol. 2017, 264:804-13. 10.1007\/s00415-016-8308-8","journal-title":"J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2018.10.009","article-title":"The Alzheimer\u2019s disease clinical spectrum: diagnosis and management","volume":"103","author":"Atri A","year":"2019","unstructured":"Atri A. The Alzheimer\u2019s disease clinical spectrum: diagnosis and management. Med Clin North Am. 2019, 103:263-93. 10.1016\/j.mcna.2018.10.009","journal-title":"Med Clin North Am"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101496","article-title":"Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer's disease: a systematic review","volume":"72","author":"Jeremic D","year":"2021","unstructured":"Jeremic D, Jim\u00e9nez-D\u00edaz L, Navarro-L\u00f3pez JD. Past, present and future of therapeutic strategies against amyloid-\u03b2 peptides in Alzheimer's disease: a systematic review. Ageing Res Rev. 2021, 72:101496. 10.1016\/j.arr.2021.101496","journal-title":"Ageing Res Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X18666200429011823","article-title":"Current status of drug targets and emerging therapeutic strategies in the management of Alzheimer's disease","volume":"18","author":"Ghosh S","year":"2020","unstructured":"Ghosh S, Durgvanshi S, Agarwal S, Raghunath M, Sinha JK. Current status of drug targets and emerging therapeutic strategies in the management of Alzheimer's disease. Curr Neuropharmacol. 2020, 18:883-903. 10.2174\/1570159X18666200429011823","journal-title":"Curr Neuropharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00754","article-title":"The important interface between apolipoprotein E and neuroinflammation in Alzheimer\u2019s disease","volume":"11","author":"Kloske CM","year":"2020","unstructured":"Kloske CM, Wilcock DM. The important interface between apolipoprotein E and neuroinflammation in Alzheimer\u2019s disease. Front Immunol. 2020, 11:754. 10.3389\/fimmu.2020.00754","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.932722","article-title":"Oxidative stress and Down syndrome. Do antioxidants play a role in therapy?","volume":"63","author":"Muchov\u00e1 J","year":"2014","unstructured":"Muchov\u00e1 J, \u017dit\u0148anov\u00e1 I, \u010eura\u010dkov\u00e1 Z. Oxidative stress and Down syndrome. Do antioxidants play a role in therapy?. Physiol Res. 2014, 63:535-42. 10.33549\/physiolres.932722","journal-title":"Physiol Res"},{"key":"ref15","article-title":"Down syndrome-genetic and nutritional aspects of accompanying disorders","volume":"66","author":"Mazurek D","year":"2015","unstructured":"Mazurek D, Wyka J. Down syndrome-genetic and nutritional aspects of accompanying disorders. Roczniki Pa\u0144stwowego Zak\u0142adu Higieny. 2015, 66:875614.","journal-title":"Roczniki Pa\u0144stwowego Zak\u0142adu Higieny"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.23751\/pn.v23i3.9335","article-title":"Usage of nutritional supplements for individuals with Down syndrome","volume":"23","author":"Ravancic ME","year":"2021","unstructured":"Ravancic ME, Obradovic V. Usage of nutritional supplements for individuals with Down syndrome. Progress in Nutrition. 2021, 23:10.23751\/pn.v23i3.9335","journal-title":"Progress in Nutrition"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci8100187","article-title":"DYRK1A protein, a promising therapeutic target to improve cognitive deficits in Down syndrome","volume":"8","author":"Feki A","year":"2018","unstructured":"Feki A, Hibaoui Y. DYRK1A protein, a promising therapeutic target to improve cognitive deficits in Down syndrome. Brain Sci. 2018, 8:10.3390\/brainsci8100187","journal-title":"Brain Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007178.pub2","article-title":"Donepezil for dementia in people with Down syndrome","author":"Mohan M","year":"2009","unstructured":"Mohan M, Carpenter PK, Bennett C. Donepezil for dementia in people with Down syndrome. Cochrane Database Syst Rev. 2009, CD007178. 10.1002\/14651858.CD007178.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007658","article-title":"Rivastigmine for dementia in people with Down syndrome","author":"Mohan M","year":"2009","unstructured":"Mohan M, Bennett C, Carpenter PK. Rivastigmine for dementia in people with Down syndrome. Cochrane Database Syst Rev. 2009, CD007658. 10.1002\/14651858.CD007658","journal-title":"Cochrane Database Syst Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.32481\/djph.2021.09.016","article-title":"Down syndrome and dementia: A patient and care-giver centered approach","volume":"7","author":"Stephens MM","year":"2021","unstructured":"Stephens MM, Herge E, Wright C. Down syndrome and dementia: A patient and care-giver centered approach. Dela J Public Health. 2021, 7:128-30. 10.32481\/djph.2021.09.016","journal-title":"Dela J Public Health"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.66","article-title":"Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial","volume":"2","author":"Boada R","year":"2012","unstructured":"Boada R, Hutaff-Lee C, Schrader A, Weitzenkamp D, Benke TA, Goldson EJ, Costa AC. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry. 2012, 2:141.","journal-title":"Transl Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00369-0","article-title":"Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"1","author":"Costa AC","year":"2022","unstructured":"Costa AC, Brand\u00e3o AC, Boada R, et al.. Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomized, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2022, 1:31-41. 10.1016\/S1474-4422(21)00369-0","journal-title":"Lancet Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007657","article-title":"Memantine for dementia in people with Down syndrome","author":"Mohan M","year":"2009","unstructured":"Mohan M, Bennett C, Carpenter PK. Memantine for dementia in people with Down syndrome. Cochrane Database Syst Rev. 2009, CD007657. 10.1002\/14651858.CD007657","journal-title":"Cochrane Database Syst Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S186760","article-title":"Vitamin E and Alzheimer\u2019s disease: what do we know so far?","volume":"14","author":"Browne D","year":"2019","unstructured":"Browne D, McGuinness B, Woodside JV, McKay GJ. Vitamin E and Alzheimer\u2019s disease: what do we know so far?. Clin Interv Aging. 2019, 14:1303-17. 10.2147\/CIA.S186760","journal-title":"Clin Interv Aging"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12903","article-title":"Accelerated bio-cognitive aging in Down syndrome: State of the art and possible deceleration strategies","volume":"18","author":"Franceschi C","year":"2019","unstructured":"Franceschi C, Garagnani P, Gensous N, Bacalini MG, Conte M, Salvioli S. Accelerated bio-cognitive aging in Down syndrome: State of the art and possible deceleration strategies. Aging Cell. 2019, 18:e12903. 10.1111\/acel.12903","journal-title":"Aging Cell"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2018.03.001","article-title":"The effect of long-term treatment with coenzyme Q10 on nucleic acid modifications by oxidation in children with Down syndrome","volume":"67","author":"Larsen EL","year":"2018","unstructured":"Larsen EL, Padella L, Bergholdt HK, et al.. The effect of long-term treatment with coenzyme Q10 on nucleic acid modifications by oxidation in children with Down syndrome. Neurobiol Aging. 2018, 67:159-61. 10.1016\/j.neurobiolaging.2018.03.001","journal-title":"Neurobiol Aging"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2020.100607","article-title":"The promotion of physical activity for the prevention of Alzheimer's disease in adults with Down Syndrome: Rationale and design for a 12\u00a0Month randomized trial","volume":"19","author":"Ptomey LT","year":"2020","unstructured":"Ptomey LT, Szabo-Reed AN, Martin LE, et al.. The promotion of physical activity for the prevention of Alzheimer's disease in adults with Down Syndrome: Rationale and design for a 12\u00a0Month randomized trial. Contemp Clin Trials Commun. 2020, 19:100607. 10.1016\/j.conctc.2020.100607","journal-title":"Contemp Clin Trials Commun"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.dhjo.2018.02.003","article-title":"Changes in cognitive function after a 12-week exercise intervention in adults with Down syndrome","volume":"11","author":"Ptomey LT","year":"2018","unstructured":"Ptomey LT, Szabo AN, Willis EA, Gorczyca AM, Greene JL, Danon JC, Donnelly JE. Changes in cognitive function after a 12-week exercise intervention in adults with Down syndrome. Disabil Health J. 2018, 11:486-90. 10.1016\/j.dhjo.2018.02.003","journal-title":"Disabil Health J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/103924-treatment-modalities-for-dementia-in-downs-syndrome-a-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:08Z","timestamp":1707507428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/103924-treatment-modalities-for-dementia-in-downs-syndrome-a-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.27881","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,11]]}}}